Cancer Chemotherapy

Withrow and MacEwen's Small Animal Clinical Oncology: Fifth Edition

Volumn , Issue , 2012, Pages 157-179

  Gustafson, Daniel L ^a,c   Page, Rodney L ^b,c  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b Flint Animal Cancer Center   (United States)

^c Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901886588     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2362-5.00011-6     Document Type: Chapter

References (294)

1. Morrison WB Cancer chemotherapy: an annotated history. J Vet Intern Med 2010, 24:1249.
2. Chabner BA, Roberts TG Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 2005, 5:65.
3. De Vita VT, Chu E A history of cancer chemotherapy. Cancer Res 2008, 68:8643.
4. Shoemaker RH The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006, 6:813.
5. Sharma SV, Haber DA, Settleman J Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 2010, 10:241.
6. Thamm DH, Rose B, Kow K, et al. Masitinib as a chemosensitizer of canine tumor cell lines: A proof of concept study. Vet J 2011, 191(1):131-134.
7. Begleiter A, Lam H-YP, Grover J, et al. Evidence for active transport of melphalan by two amino acid carriers in L5178Y lymphoblasts in vitro. Cancer Res 1979, 39:353.
8. Vistica D Cytotoxicity as an indicator for transport mechanism: evidence that murine bone marrow progenitor cells lack a high-affinity leucine carrier that transports melphalan in murine L1210 leukemia cells. Blood 1980, 56:427.
9. Wiley JS, Jones SP, Sawyer WH, et al. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest 1982, 69:479.
10. Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998, 58:4349.
11. Goldman ID, Lichtenstein NS, Oliverio VT Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem 1968, 243:5007.
12. Withoff S, Keith WN, Knol AJ, et al. Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer 1996, 74:502.
13. Wang H, Jiang Z, Wong YW, et al. Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIalpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226. Biochem Biophys Res Commun 1997, 237:217.
14. Moran RG, Spears CP, Heidelberger C Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2′-deoxyuridylate, 2′-deoxyuridylate, and thymidylate synthetase. Proc Natl Acad Sci U S A 1979, 76:1456.
15. Karran P, Bignami M DNA damage tolerance, mismatch repair and genome instability. BioEssays 1994, 16:833.
16. Brown JM, Attardi LD The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005, 5:231.
17. Igney FH, Krammer PH Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002, 2:277.
18. Reed JC, Kitada S, Takayama S, et al. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 1994, 5(Suppl 1):61.
19. Schmitt CA, Rosenthal CT, Lowe SW Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000, 6:1029.
20. Ambrosini G, Adida C, Altieri DC A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917.
21. Kramer M, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996, 14:2131.
22. Sohn SK, Jung JT, Kim DH, et al. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. Am J Hematol 2003, 73:101.
23. Rebhun RB, Lana SE, Ehrhart EJ, et al. Comparative analysis of survivin expression in untreated and relapsed canine lymphoma. J Vet Intern Med 2008, 22:989.
24. Moscow JA, Swanson CA, Cowan KH Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br J Cancer 1993, 68:732.
25. Saikawa Y, Knight CB, Saikawa T, et al. Decreased expression of the human folate receptor mediates transport-defective methotrexate resistance in KB cells. J Biol Chem 1993, 268:5293.
26. Tew KD Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994, 54:4313.
27. Wang AL, Tew KD Increased glutathione-S-transferase activity in a cell line with acquired resistance to nitrogen mustards. Cancer Treat Rep 1985, 69:677.
28. Lewis AD, Hickson ID, Robson CN, et al. Amplification and increased expression of alpha class glutathione S-transferase-encoding genes associated with resistance to nitrogen mustards. Proc Natl Acad Sci U S A 1988, 85:8511.
29. Beck A, Etienne MC, Cheradame S, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994, 30A:1517.
30. Ishikawa Y, Kubota T, Otani Y, et al. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 1999, 5:883.
31. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000, 24:236.
32. Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987, 47:2203.
33. Heinemann V, Xu YZ, Chubb S, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 1990, 38:567.
34. Huang P, Chubb S, Hertel LW, et al. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991, 51:6110.
35. Heinemann V, Hertel LW, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988, 48:4024.
36. Bouffard DY, Laliberte J, Momparler RL Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 1993, 45:1857.
37. Ohhashi S, Ohuchida K, Mizumoto K, et al. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. Anticancer Res 2008, 28:2205.
38. Nakano Y, Tanno S, Koizumi K, et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007, 96:457.
39. Long BH, Wang L, Lorico A, et al. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res 1991, 51:5275.
40. Minocha A, Long BH Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26. Biochem Biophys Res Commun 1984, 122:165.
41. Chen GL, Yang L, Rowe TC, et al. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984, 259:13560.
42. Alt FW, Kellems RE, Bertino JR, et al. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 1978, 253:1357.
43. Giannakakou P, Sackett DL, Kang Y-K, et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997, 272:17118.
44. Andoh T, Ishii K, Suzuki Y, et al. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci U S A 1987, 84:5565.
45. Chaney SG, Sancar A DNA repair: Enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996, 88:1346.
46. Behrens BC, Hamilton TC, Masuda H, et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987, 47:414.
47. Masuda H, Tanaka T, Matsuda H, et al. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res 1990, 50:1863.
48. Parker RJ, Eastman A, Bostick-Bruton F, et al. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991, 87:772.
49. Nojima K, Hochegger H, Saberi A, et al. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res 2005, 65:11704.
50. Borst P, Elferink RO Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002, 71:537.
51. Fletcher JI, Haber M, Henderson MJ, et al. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010, 10:147.
52. Lee JJ, Hughes CS, Fine RL, et al. P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer 1996, 77:1892.
53. Honscha KU, Schirmer A, Reischauer A, et al. Expression of ABC-transport proteins in canine mammary cancer: Consequences for chemotherapy. Reprod Domest Anim 2009, 44(Suppl 2):218.
54. Hifumi T, Miyoshi N, Kawaguchi H, et al. Immunohistochemical detection of proteins associated with multidrug resistance to anti-cancer drugs in canine and feline primary pulmonary carcinoma. J Vet Med Sci 2010, 72:665.
55. Nowak M, Madej JA, Dziegiel P Expression of breast cancer resistance protein (BCRP-1) in canine mammary adenocarcinomas and adenomas. In Vivo 2009, 23:705.
56. Conrad S, Viertelhaus A, Orzechowski A, et al. Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1. Toxicology 2001, 156:81.
57. Yabuuchi H, Tanaka K, Maeda M, et al. Cloning of the dog bile salt export pump (BSEP; ABCB11) and functional comparison with the human and rat proteins. Biopharm Drug Dispos 2008, 29:441.
58. Ramirez CJ, Minch JD, Gay JM, et al. Molecular genetic basis for fluoroquinolone-induced retinal degeneration in cats. Pharmacogenet Genomics 2011, 21:66.
59. Chabner BA Clinical strategies for cancer treatment: the role of drugs. Cancer chemotherapy: Principles and practice 1990, JB Lippincott, Philadelphia. B.A. Chabner, J.M. Collins (Eds.).
60. Page RL, Macy DW, Ogilvie GK, et al. Phase III evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphoma. Int J Hyperthermia 1992, 8:187.
61. Carter RF, Harris CK, Withrow SJ, et al. Chemotherapy of canine lymphoma with histopathological correlation- doxorubicin alone compared to COP as 1st treatment regimen. J Am Anim Hosp Assoc 1987, 23:587.
62. Postorino NC, Susaneck SJ, Withrow SJ, et al. Single agent therapy with adriamycin for canine lymphosarcoma. J Am Anim Hosp Assoc 1989, 25:221.
63. Valerius KD, Ogilvie GK, Mallinckrodt CH, et al. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). J Am Vet Med Assoc 1997, 210:512.
64. Mutsaers AJ, Glickman NW, De Nicola DB, et al. Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs. J Am Vet Med Assoc 2002, 220:1813.
65. Cotter SM Treatment of lymphoma and leukemia with cyclophosphamide, vincristine, and prednisone. 1. Treatment of Dogs. J Am Anim Hosp Assoc 1983, 19:159.
66. Mac Ewen EG, Brown NO, Patnaik AK, et al. Cyclic combination chemotherapy of canine lymphosarcoma. J Am Vet Med Assoc 1981, 178:1178.
67. Mac Ewen EG, Hayes AA, Matus RE, et al. Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog-147 Cases (1978-1981). J Am Vet Med Assoc 1987, 190:564.
68. Khanna C, Lund EM, Redic KA, et al. Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma. J Am Vet Med Assoc 1998, 213:985.
69. Greenlee PG, Filippa DA, Quimby FW, et al. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 1990, 66:480.
70. Stone MS, Goldstein MA, Cotter SM Comparison of 2 protocols for induction of remission in dogs with lymphoma. J Am Anim Hosp Assoc 1991, 27:315.
71. Myers NC, Moore AS, Rand WM, et al. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma. J Vet Intern Med 1997, 11:333.
72. Boyce KL, Kitchell BE Treatment of canine lymphoma with COPLA/LVP. J Am Anim Hosp Assoc 2000, 36:395.
73. Morrison-Collister KE, Rassnick KM, Northrup NC, et al. A combination chemotherapy protocol with MOPP and CCNU consolidation (Tufts VELCAP-SC) for the treatment of canine lymphoma. Vet Comp Oncol 2003, 1:180.
74. Zemann BI, Moore AS, Rand WM, et al. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. J Vet Intern Med 1998, 12:465.
75. Keller ET, Mac Ewen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993, 7:289.
76. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002, 16:704.
77. Undevia SD, Gomez-Abuin G, Ratain MJ Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005, 5:447.
78. Bailey DB, Rassnick KM, Erb HN, et al. Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors. Am J Vet Res 2004, 65:1502.
79. Mealey KL, Fidel J, Gay JM, et al. ABCB1-1Delta polymorphism can predict hematologic toxicity in dogs treated with vincristine. J Vet Intern Med 2008, 22:996.
80. Thompson LA, Lawson AP, Sutphin SD, et al. Description of current practices of empiric chemotherapy dose adjustment in obese adult patients. J Oncol Pract 2010, 6:141.
81. Hunter RJ, Navo MA, Thaker PH, et al. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev 2009, 35:69.
82. Vail DM Supporting the veterinary cancer patient on chemotherapy: neutropenia and gastrointestinal toxicity. Top Companion Anim Med 2009, 24:122.
83. Dranitsaris G, Johnston M, Poirier S, et al. Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature. J Oncol Pharm Pract 2005, 11:69.
84. Hamscher G, Mohring SA, Knobloch A, et al. Determination of drug residues in urine of dogs receiving anti-cancer chemotherapy by liquid chromatography-electrospray ionization- tandem mass spectrometry: is there an environmental or occupational risk?. J Anal Toxicol 2010, 34:142.
85. Evans WE, Relling MV Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989, 16:327.
86. Eckhoff GA Mechanisms of adverse drug-reactions and interactions in veterinary-medicine. J Am Vet Med Assoc 1980, 176:1131.
87. He SM, Yang AK, Li XT, et al. Effects of herbal products on the metabolism and transport of anticancer agents. Expert Opin Drug Metab Toxicol 2010, 6:1195.
88. Tarirai C, Viljoen AM, Hamman JH Herb-drug pharmacokinetic interactions reviewed. Expert Opin Drug Metab Toxicol 2010, 6:1515.
89. Mealey KL Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther 2004, 27:257.
90. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982, 96:133.
91. Berrak SG, Ewer MS, Jaffe N, et al. Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep 2001, 8:611.
92. Preisler HD, Gessner T, Azarnia N, et al. Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 1984, 12:125.
93. Piscitelli SC, Rodvold KA, Rushing DA, et al. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 1993, 53:555.
94. Danesi R, Fogli S, Gennari A, et al. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 2002, 41:431.
95. Arrington KA, Legendre AM, Tabeling GS, et al. Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs. Am J Vet Res 1994, 55:1587.
96. Veterinary co-operative oncology group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004, 2:195.
97. Bailey DB, Rassnick KM, Kristal O, et al. Phase I dose escalation of single-agent vinblastine in dogs. J Vet Intern Med 2008, 22:1397.
98. Vaughan A, Johnson JL, Williams LE Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol. J Vet Intern Med 2007, 21:1332.
99. Eschalier A, Lavarenne J, Burtin C, et al. Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 1988, 21:246.
100. Poirier VJ, Hershey AE, Burgess KE, et al. Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. J Vet Intern Med 2004, 18:219.
101. Goodman LS, Wintrobe MM, et al. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc 1946, 132:126.
102. Jacobson LO, Spurr CL, et al. Studies on the effect of methyl bis (beta-chloroethyl) amine hydrochloride on diseases of the hemopoietic system. J Clin Invest 1946, 25:909.
103. Rhoads CP Nitrogen mustards in the treatment of neoplastic disease; official statement. J Am Med Assoc 1946, 131:656.
104. Kohn KW, Spears CL, Doty P Inter-strand crosslinking of DNA by nitrogen mustard. J Mol Biol 1966, 19:266.
105. Skipper HE, Bennett LL, Langham WH Over-all tracer studies with C14 labeled nitrogen mustard in normal and leukemic mice. Cancer 1951, 4:1025.
106. Goldenberg GJ, Vanstone CL, Israels LG, et al. Evidence for a transport carrier of nitrogen mustard in nitrogen mustard-sensitive and -resistant L5178Y lymphoblasts. Cancer Res 1970, 30:2285.
107. Rassnick KM, Mauldin GE, Al-Sarraf R, et al. MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases. J Vet Intern Med 2002, 16:1989-2000.
108. Rassnick KM, Bailey DB, Malone EK, et al. Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs. Vet Comp Oncol 2010, 8:243.
109. Brodsky EM, Maudlin GN, Lachowicz JL, et al. Asparaginase and MOPP treatment of dogs with lymphoma. J Vet Intern Med 2009, 23:578.
110. Tew KD, Colvin OM, Chabner BA Alkylating agents. Cancer chemotherapy & biotherapy: principles and practice 2001, Lippincott Williams & Wilkins, Philadelphia. B.A. Chabner, D.L. Longo (Eds.).
111. Cohen JL, Jao JY Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat. J Pharmacol Exp Ther 1970, 174:206.
112. Colvin M, Brundrett RB, Kan MN, et al. Alkylating properties of phosphoramide mustard. Cancer Res 1976, 36:1121.
113. Warry E, Hansen RJ, Gustafson DL, et al. Pharmacokinetics of cyclophosphamide after oral and intravenous administration to dogs with lymphoma. J Vet Intern Med 2011, 25:903.
114. Fetting JH, McCarthy LE, Borison HL, et al. Vomiting induced by cyclophosphamide and phosphoramide mustard in cats. Cancer Treat Rep 1982, 66:1625.
115. Lori JC, Stein TJ, Thamm DH Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study. Vet Comp Oncol 2010, 8:188.
116. Hadden AG, Cotter SM, Rand W, et al. Efficacy and toxicosis of VELCAP-C treatment of lymphoma in cats. J Vet Intern Med 2008, 22:153.
117. Creaven PJ, Allen LM, Alford DA, et al. Clinical pharmacology of isophosphamide. Clin Pharmacol Ther 1974, 16:77.
118. Norpoth K Studies on the metabolism of isopnosphamide (NSC-109724) in man. Cancer Treat Rep 1976, 60:437.
119. Lind MJ, Roberts HL, Thatcher N, et al. The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 1990, 26:105.
120. Rassnick KM, Frimberger AE, Wood CA, et al. Evaluation of ifosfamide for treatment of various canine neoplasms. J Vet Intern Med 2000, 14:271.
121. Rassnick KM, Moore AS, Northrup NC, et al. Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas. Am J Vet Res 2006, 67:510.
122. Rassnick KM, Rodriguez CO, Khanna C, et al. Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas. Am J Vet Res 2006, 67:517.
123. Begleiter A, Goldenberg GJ Uptake and decomposition of chlorambucil by L5178Y lymphoblasts in vitro. Biochem Pharmacol 1983, 32:535.
124. Jiang BZ, Bank BB, Hsiang YH, et al. Lack of drug-induced DNA cross-links in chlorambucil-resistant Chinese hamster ovary cells. Cancer Res 1989, 49:5514.
125. Mitoma C, Onodera T, Takegoshi T, et al. Metabolic disposition of chlorambucil in rats. Xenobiotica 1977, 7:205.
126. Goodman GE, McLean A, Alberts DS, et al. Inhibition of human tumour clonogenicity by chlorambucil and its metabolites. Br J Cancer 1982, 45:621.
127. Stein TJ, Pellin M, Steinberg H, et al. Treatment of feline gastrointestinal small-cell lymphoma with chlorambucil and glucocorticoids. J Am Anim Hosp Assoc 2010, 46:413.
128. Begleiter A, Lam HP, Goldenberg GJ Mechanism of uptake of nitrosoureas by L5178Y lymphoblasts in vitro. Cancer Res 1977, 37:1022.
129. Montgomery JA, James R, McCaleb GS, et al. The modes of decomposition of 1,3-bis(2-chloroethyl)-1-nitrosourea and related compounds. J Med Chem 1967, 10:668.
130. Colvin M, Brundrett RB, Cowens W, et al. A chemical basis for the antitumor activity of chloroethylnitrosoureas. Biochem Pharmacol 1976, 25:695.
131. Kohn KW Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas. Cancer Res 1977, 37:1450.
132. Hill DL, Kirk MC, Struck RF Microsomal metabolism of nitrosoureas. Cancer Res 1975, 35:296.
133. Wheeler GP, Johnston TP, Bowdon BJ, et al. Comparison of the properties of metabolites of CCNU. Biochem Pharmacol 1977, 26:2331.
134. Lee FY, Workman P, Roberts JT, et al. Clinical pharmacokinetics of oral CCNU (lomustine). Cancer Chemother Pharmacol 1985, 14:125.
135. Heading KL, Brockley LK, Bennett PF CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07). Aust Vet J 2011, 89:109.
136. Hosoya K, Lord LK, Lara-Garcia A, et al. Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (Lomustine). Vet Comp Oncol 2009, 7:244.
137. Skorupski KA, Hammond GM, Irish AM, et al. Prospective randomized clinical trial assessing the efficacy of denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs. J Vet Intern Med 2011, 25:838.
138. Reusser F Mode of action of streptozotocin. J Bacteriol 1971, 105:580.
139. Bhuyan BK The action of streptozotocin on mammalian cells. Cancer Res 1970, 30:2017.
140. Schnedl WJ, Ferber S, Johnson JH, et al. STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 1994, 43:1326.
141. Hosokawa M, Dolci W, Thorens B Differential sensitivity of GLUT1- and GLUT2-expressing beta cells to streptozotocin. Biochem Biophys Res Commun 2001, 289:1114.
142. Adolphe AB, Glasofer ED, Troetel WM, et al. Preliminary pharmacokinetics of streptozotocin, an antineoplastic antibiotic. J Clin Pharmacol 1977, 17:379.
143. Schein PS, Cooney DA, Vernon ML The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity. Cancer Res 1967, 27:2324.
144. Schein PS, Rakieten N, Cooney DA, et al. Streptozotocin diabetes in monkeys and dogs, and its prevention by nicotinamide. Proc Soc Exp Biol Med 1973, 143:514.
145. Schein PS 1-methyl-1-nitrosourea and dialkylnitrosamine depression of nicotinamide adenine dinucleotide. Cancer Res 1969, 29:1226.
146. Panasci LC, Fox PA, Schein PS Structure-activity studies of methylnitrosourea antitumor agents with reduced murine bone marrow toxicity. Cancer Res 1977, 37:3321.
147. Moore AS, Nelson RW, Henry CJ, et al. Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 cases (1989-1999). J Am Vet Med Assoc 2002, 221:811.
148. Audette RC, Connors TA, Mandel HG, et al. Studies on the mechanism of action of the tumour inhibitory triazenes. Biochem Pharmacol 1973, 22:1855.
149. Reid JM, Kuffel MJ, Miller JK, et al. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res 1999, 5:2192.
150. Nagasawa HT, Shirota FN, Mizuno NS The mechanism of alkylation of DNA by 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MIC), a metabolite of DIC (NSC-45388). Non-involvement of diazomethane. Chem Biol Interact 1974, 8:403.
151. Kleihues P, Kolar GF, Margison GP Interaction of the carcinogen 3,3-dimethyl-1-phenyltriazene with nucleic acids of various rat tissues and the effect of a protein-free diet. Cancer Res 1976, 36:2189.
152. Griessmayr PC, Payne SE, Winter JE, et al. Dacarbazine as single-agent therapy for relapsed lymphoma in dogs. J Vet Intern Med 2009, 23:1227.
153. Flory AB, Rassnick KM, Al-Sarraf R, et al. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs. J Vet Intern Med 2008, 22:164.
154. Gale GR, Simpson JG, Smith AB Studies of the mode of action of N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide. Cancer Res 1967, 27:1186.
155. Moloney SJ, Wiebkin P, Cummings SW, et al. Metabolic activation of the terminal N-methyl group of N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride (procarbazine). Carcinogenesis 1985, 6:397.
156. Schold SC, Brent TP, von Hofe E, et al. O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J Neurosurg 1989, 70:573.
157. Shiba DA, Weinkam RJ Quantitative analysis of procarbazine, procarbazine metabolites and chemical degradation products with application to pharmacokinetic studies. J Chromatogr 1982, 229:397.
158. Oliverio VT, Denham C, Devita VT, et al. Some pharmacologic properties of a new antitumor agent, N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide, hydrochloride (Nsc-77213). Cancer Chemother Rep 1964, 42:1.
159. Chabner BA, Sponzo R, Hubbard S, et al. High-dose intermittent intravenous infusion of procarbazine (NSC-77213). Cancer Chemother Rep 1973, 57:361.
160. Zunino F, Gambetta R, Di Marco A The inhibition in vitro of DNA polymerase and RNA polymerase by daunomycin and Adriamycin. Biochem Pharmacol 1975, 24:309.
161. Tewey KM, Chen GI, Nelson EM, et al. Intercalative anti-tumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase. J Biol Chem 1984, 259:9182.
162. Taatjes DJ, Gaudiano G, Resing K, et al. Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J Med Chem 1996, 39:4135.
163. Doroshow JH Role of hydrogen peroxide and hydroxyl radical in the killing of ehrlich tumor cells by anticancer quinones. Proc Natl Acad Sci U S A 1985, 83:4514.
164. Bachur NR, Gordon SL, Gee MV A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 1978, 38:1745.
165. Pessah IN, Durie EL, Schiedt MJ, et al. Anthraquinone-sensitized Ca + release channel from rat cardiac sarcoplasmic reticulum: possible receptor-mediated mechanism of doxorubicin cardiomyopathy. Mol Pharmacol 1990, 37:503.
166. Oakes SG, Schlager JJ, Santone KS, et al. Doxorubicin blocks the increase in intracellular Ca ++, part of a second messenger system in N1E-115 murine neuroblastoma cells. J Pharmacol Exp Ther 1990, 252:979.
167. Mau BL, Powis G Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin: relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity. Biochem Pharmacol 1992, 43:1621.
168. Morre DJ, Kim C, Paulik M, et al. Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin?. J Bioenerg Biomembr 1997, 29:269.
169. Terasaki T, Iga T, Sugiyama Y, et al. Experimental evidence of characteristic tissue distribution of Adriamycin: tissue DNA concentration as a determinant. J Pharm Pharmacol 1982, 34:597.
170. Nicolay K, Timmers RJM, Spoelstra E, et al. The interaction of adriamycin with cardiolipin in model and rat liver mitochondrial membranes. Biochim Biophys Acta 1984, 778:359.
171. Goormaghtigh E, Chatelain P, Caspers J, et al. Evidence of a specific complex between adriamycin and negatively-charged phospholipids. Biochim Biophys Acta 1980, 597:1.
172. Gustafson DL, Rastatter JC, Colombo T, et al. Doxorubicin pharmacokinetics: macromolecule binding, metabolism and elimination in the context of a physiological model. J Pharm Sci 2002, 91:1488.
173. Ahmed NK, Felsted RL, Bachur NR Daunorubicin reduction mediated by aldehyde and ketone reductases. Xenobiotica 1981, 11:131.
174. Pan SS, Bachur NR Xanthine oxidase catalyzed reductive cleavage of anthracycline antibiotics and free radical formation. Mol Pharmacol 1980, 17:95.
175. Young RC, Ozols RF, Myers CE The anthracycline neoplastic drugs. N Engl J Med 1981, 305:139.
176. O'Keefe DA, Sisson DD, Gelberg HB, et al. Systemic toxicity associated with doxorubicin administration in cats. J Vet Intern Med 1993, 7:309.
177. Thamm DH, Vail DM Aftershocks of cancer chemotherapy: managing adverse effects. J Am Anim Hosp Assoc 2007, 43:1.
178. Foye WO, Vajragupta O, Sengupta SK DNA-binding specificity and RNA polymerase inhibitory activity of bis(aminoalkyl)anthraquinones and bis(methylthio)vinylquinolinium iodides. J Pharm Sci 1982, 71:253.
179. Crespi MD, Ivanier SE, Genovese J, et al. Mitoxantrone affects topoisomerase activities in human breast cancer cells. Biochem Biophys Res Commun 1986, 136:521.
180. Patterson LH, Gandecha BM, Brown JR 1,4-Bis(2-[(2-hydroxyethyl)amino]ethylamino)-9,10-anthracenedione, an anthraquinone antitumour agent that does not cause lipid peroxidation in vivo; comparison with daunorubicin. Biochem Biophys Res Commun 1983, 110:399.
181. Nguyen B, Gutierrez PL Mechanism(s) for the metabolism of mitoxantrone: electron spin resonance and electrochemical studies. Chem Biol Interact 1990, 74:139.
182. Alberts DS, Peng YM, Leigh S, et al. Disposition of mitoxantrone in cancer patients. Cancer Res 1985, 45:1879.
183. Lu K, Savaraj N, Loo TL Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride in the dog. Cancer Chemother Pharmacol 1984, 13:63.
184. Chiccarelli FS, Morrison JA, Cosulich DB, et al. Identification of human urinary mitoxantrone metabolites. Cancer Res 1986, 46:4858.
185. Henry CJ, McCaw DL, Turnquist SE, et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res 2003, 9:906.
186. Takusagawa F, Dabrow M, Neidle S, et al. The structure of a pseudo intercalated complex between actinomycin and the DNA binding sequence d(GpC). Nature 1982, 296:466.
187. Takusagawa F, Goldstein BM, Youngster S, et al. Crystallization and preliminary X-ray study of a complex between d(ATGCAT) and actinomycin D. J Biol Chem 1984, 259:4714.
188. Brown SC, Mullis K, Levenson C, et al. Aqueous solution structure of an intercalated actinomycin D-dATGCAT complex by two-dimensional and one-dimensional proton NMR. Biochemistry 1984, 23:403.
189. Wadkins RM, Jovin TM Actinomycin D and 7-aminoactinomycin D binding to single-stranded DNA. Biochemistry 1991, 30:9469.
190. Goldberg IH, Rabinowitz M, Reich E Basis of actinomycin action. I. DNA binding and inhibition of RNA-polymerase synthetic reactions by actinomycin. Proc Natl Acad Sci U S A 1962, 48:2094.
191. Reich E, Franklin RM, Shatkin AJ, et al. Action of actinomycin D on animal cells and viruses. Proc Natl Acad Sci U S A 1962, 48:1238.
192. Kessel D, Wodinsky I Uptake in vivo and in vitro of actinomycin D by mouse leukemias as factors in survival. Biochem Pharmacol 1968, 17:161.
193. Inaba M, Johnson RK Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia. Cancer Res 1977, 37:4629.
194. Diddens H, Gekeler V, Neumann M, et al. Characterization of actinomycin-D-resistant CHO cell lines exhibiting a multidrug-resistance phenotype and amplified DNA sequences. Int J Cancer 1987, 40:635.
195. Galbraith WM, Mellett LB Tissue disposition of 3H-actinomycin D (NSC-3053) in the rat, monkey, and dog. Cancer Chemother Rep 1975, 59:1601.
196. Furth JJ, Cohen SS Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-beta-d-arabinofuranosylcytosine and the 5′-triphosphate of 9-beta-d-arabinofuranoxyladenine. Cancer Res 1968, 28:2061.
197. Kufe DW, Major PP, Egan EM, et al. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 1980, 255:8997.
198. Major PP, Egan EM, Herrick DJ, et al. Effect of ARA-C incorporation on deoxyribonucleic acid synthesis in cells. Biochem Pharmacol 1982, 31:2937.
199. Mikita T, Beardsley GP Functional consequences of the arabinosylcytosine structural lesion in DNA. Biochemistry 1988, 27:4698.
200. Bianchi Scarra GL, Romani M, Coviello DA, et al. Terminal erythroid differentiation in the K-562 cell line by 1-beta-D-arabinofuranosylcytosine: accompaniment by c-myc messenger RNA decrease. Cancer Res 1986, 46:6327.
201. Plagemann PG, Marz R, Wohlhueter RM Transport and metabolism of deoxycytidine and 1-beta-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis. Cancer Res 1978, 38:978.
202. Garcia-Carbonero R, Ryan DP, Chabner BA Cytidine analogs. Cancer chemotherapy & biotherapy: Principles and practice 2001, Lippincott Williams & Wilkins, Philadelphia. B.A. Chabner, D.L. Longo (Eds.).
203. Ho DH, Frei E Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Clin Pharmacol Ther 1971, 12:944.
204. Menaut P, Landart J, Behr S, et al. Treatment of 11 dogs with meningoencephalomyelitis of unknown origin with a combination of prednisolone and cytosine arabinoside. Vet Rec 2008, 162:241.
205. Smith PM, Stalin CE, Shaw D, et al. Comparison of two regimens for the treatment of meningoencephalomyelitis of unknown etiology. J Vet Intern Med 2009, 23:520.
206. Marconato L, Bonfanti U, Stefanello D, et al. Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference?. Vet Comp Oncol 2008, 6:80.
207. Allegra CJ, Fine RL, Drake JC, et al. The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells. Evidence for direct inhibition of purine synthesis. J Biol Chem 1986, 261:6478.
208. Allegra CJ, Chabner BA, Drake JC, et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985, 260:9720.
209. Fabre I, Fabre G, Goldman ID Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res 1984, 44:3190.
210. Wan SH, Huffman DH, Azarnoff DL, et al. Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res 1974, 34:3487.
211. Bischoff KB, Dedrick RL, Zaharko DS, et al. Methotrexate pharmacokinetics. J Pharm Sci 1971, 60:1128.
212. Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998, 58:4349.
213. Gandhi V, Plunkett W Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 1990, 50:3675.
214. Gandhi V, Legha J, Chen F, et al. Excision of 2′,2′-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res 1996, 56:4453.
215. Huang P, Plunkett W Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995, 36:181.
216. Veltkamp SA, Pluim D, van Eijndhoven MA, et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine. Mol Cancer Ther 2008, 7:2415.
217. Veltkamp SA, Jansen RS, Callies S, et al. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res 2008, 14:3477.
218. Veltkamp SA, Pluim D, van Tellingen O, et al. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. Drug Metab Dispos 2008, 36:1606.
219. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003, 21:3402.
220. Turner AI, Hahn KA, Rusk A, et al. Single agent gemcitabine chemotherapy in dogs with spontaneously occurring lymphoma. J Vet Intern Med 2006, 20:1384.
221. Le Blanc AK, La Due TA, Turrel JM, et al. Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: a veterinary radiation therapy oncology group pilot study. Vet Radiol Ultrasound 2004, 45:466.
222. Martinez-Ruzafa I, Dominguez PA, Dervisis NG, et al. Tolerability of gemcitabine and carboplatin doublet therapy in cats with carcinomas. J Vet Intern Med 2009, 23:570.
223. Jones PD, de Lorimier LP, Kitchell BE, et al. Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma. J Am Anim Hosp Assoc 2003, 39:463.
224. Dominguez PA, Dervisis NG, Cadile CD, et al. Combined gemcitabine and carboplatin therapy for carcinomas in dogs. J Vet Intern Med 2009, 23:130.
225. Marconato L, Lorenzo RM, Abramo F, et al. Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs. Vet Comp Oncol 2008, 6:90.
226. Marconato L, Zini E, Lindner D, et al. Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 2011, 238:1004.
227. McMahon M, Mathie T, Stingle N, et al. Adjuvant carboplatin and gemcitabine combination chemotherapy postamputation in canine appendicular osteosarcoma. J Vet Intern Med 2011, 25:511.
228. Wohlhueter RM, McIvor RS, Plagemann PG Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol 1980, 104:309.
229. Reyes P The synthesis of 5-fluorouridine 5′-phosphate by a pyrimidine phosphoribosyltransferase of mammalian origin. I. Some properties of the enzyme from P1534J mouse leukemic cells. Biochemistry 1969, 8:2057.
230. Houghton JA, Houghton PJ Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma. Eur J Cancer Clin Oncol 1983, 19:807.
231. Snavely NR, Snavely DA, Wilson BB Toxic effects of fluorouracil cream ingestion on dogs and cats. Arch Dermatol 2010, 146:1195.
232. Kufe DW, Major PP 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem 1981, 256:9802.
233. Kufe DW, Major PP, Egan EM, et al. 5-Fluoro-2′-deoxyuridine incorporation in L1210 DNA. J Biol Chem 1981, 256:8885.
234. Tanaka M, Yoshida S, Saneyoshi M, et al. Utilization of 5-fluoro-2′-deoxyuridine triphosphate and 5-fluoro-2′-deoxycytidine triphosphate in DNA synthesis by DNA polymerases alpha and beta from calf thymus. Cancer Res 1981, 41:4132.
235. Santi DV, McHenry CS, Sommer H Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974, 13:471.
236. Naguib FN, El Kouni MH, Cha S Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985, 45:5405.
237. Grem JL 5-fluoropyrimidines. Cancer chemotherapy & biotherapy: principles and practice 2001, Lippincott Williams & Wilkins, Philadelphia. B.A. Chabner, D.L. Longo (Eds.).
238. Schiff PB, Fant J, Horwitz SB Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277:665.
239. Schiff PB, Horwitz SB Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980, 77:1561.
240. Ringel I, Horwitz SB Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991, 83:288.
241. Jordan MA, Toso RJ, Thrower D, et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A 1993, 90:9552.
242. Bissery MC, Guenard D, Gueritte-Voegelein F, et al. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991, 51:4845.
243. Diaz JF, Andreu JM Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993, 32:2747.
244. McEntee M, Silverman JA, Rassnick K, et al. Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. Vet Comp Oncol 2003, 1:105.
245. McEntee MC, Rassnick KM, Bailey DB, et al. Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing cats. J Vet Intern Med 2006, 20:1370.
246. McEntee MC, Rassnick KM, Lewis LD, et al. Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs. Am J Vet Res 2006, 67:1057.
247. Shiu KB, McCartan L, Kubicek L, et al. Intravenous administration of docetaxel to cats with cancer. J Vet Intern Med 2011, 25:916.
248. Correia JJ Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol Ther 1991, 52:127.
249. Wilson L, Jordan MA, Morse A, et al. Interaction of vinblastine with steady-state microtubules in vitro. J Mol Biol 1982, 159:125.
250. Bruchovsky N, Owen AA, Becker AJ, et al. Effects of vinblastine on the proliferative capacity of L cells and their progress through the division cycle. Cancer Res 1965, 25:1232.
251. Tucker RW, Owellen RJ, Harris SB Correlation of cytotoxicity and mitotic spindle dissolution by vinblastine in mammalian cells. Cancer Res 1977, 37:4346.
252. Creasey WA, Marsh JC Metabolism of vinblastine (VBL) in the dog. Proceedings of the American Association for Cancer Research 1973, 14:57. (abstract).
253. Vickery KR, Wilson H, Vail DM, et al. Dose-escalating vinblastine for the treatment of canine mast cell tumour. Vet Comp Oncol 2008, 6:111.
254. Grant IA, Rodriguez CO, Kent MS, et al. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors. J Vet Intern Med 2008, 22:388.
255. Poirier VJ, Burgess KE, Adams WM, et al. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med 2004, 18:536.
256. Minocha A, Long BH Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26. Biochem Biophys Res Commun 1984, 122:165.
257. Chen GL, Yang L, Rowe TC, et al. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984, 259:13560.
258. Long BH, Musial ST, Brattain MG Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res 1985, 45:3106.
259. Sullivan DM, Latham MD, Ross WE Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res 1987, 47:3973.
260. Flory AB, Rassnick KM, Balkman CE, et al. Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs. Am J Vet Res 2008, 69:1316.
261. Pommier YG, Goldwasser F, Strumberg D Topoisomerase II inhibitors: epipodophyllotoxins, acridines, ellipticines, and bisdioxopiperazines. Cancer chemotherapy & biotherapy: principles and practice 2001, Lippincott Williams & Wilkins, Philadelphia. B.A. Chabner, D.L. Longo (Eds.).
262. Baxter JD, Harris AW, Tomkins GM, et al. Glucocorticoid receptors in lymphoma cells in culture: relationship to glucocorticoid killing activity. Science 1971, 171:189.
263. Greenstein S, Ghias K, Krett NL, et al. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 2002, 8:1681.
264. Moalli PA, Rosen ST Glucocorticoid receptors and resistance to glucocorticoids in hematologic malignancies. Leuk Lymphoma 1994, 15:363.
265. Fichtinger-Schepman AM, van der Veer JL, Den Hartog JH, et al. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 1985, 24:707.
266. Zwelling LA, Anderson T, Kohn KW DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 1979, 39:365.
267. Reed E, Kohn KW, Chabner BA, et al. Platinum analogues. Cancer chemotherapy: principles and practice 1990, JB Lippincott, Philadelphia.
268. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748.
269. Bailey DB, Rassnick KM, Erb HN, et al. Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors. Am J Vet Res 2004, 65:1502.
270. Kisseberth WC, Vail DM, Yaissle J, et al. Phase I clinical evaluation of carboplatin in tumor-bearing cats: a Veterinary Cooperative Oncology Group study. J Vet Intern Med 2008, 22:83.
271. Morgan JS, Creasey DC, Wright JA Evidence that the antitumor agent hydroxyurea enters mammalian cells by a diffusion mechanism. Biochem Biophys Res Commun 1986, 134:1254.
272. Turner MK, Abrams R, Lieberman I Meso-alpha, beta-diphenylsuccinate and hydroxyurea as inhibitors of deoxycytidylate synthesis in extracts of Ehrlich ascites and L cells. J Biol Chem 1966, 241:5777.
273. Skoog L, Nordenskjold B Effects of hydroxyurea and 1-beta-D-arabinofuranosyl-cytosine on deoxyribonucleotide pools in mouse embryo cells. Eur J Biochem 1971, 19:81.
274. Veer Reddy GP, Pardee AB Inhibitor evidence for allosteric interaction in the replitase multienzyme complex. Nature 1983, 304:86.
275. Bianchi V, Pontis E, Reichard P Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem 1986, 261:16037.
276. Rassnick KM, Al-Sarraf R, Bailey DB, et al. Phase II open-label study of single-agent hydroxyurea for treatment of mast cell tumours in dogs. Vet Comp Oncol 2010, 8:103.
277. Story MD, Voehringer DW, Stephens LC, et al. L-asparaginase kills lymphoma cells by apoptosis. Cancer Chemother Pharmacol 1993, 32:129.
278. Chabner BA, Sallan SE Enzyme therapy: L-asparaginase. Cancer chemotherapy & biotherapy: principles and practice 2001, Lippincott Williams & Wilkins, Philadelphia. B.A. Chabner, D.L. Longo (Eds.).
279. Su AI, Welsh JB, Sapinoso LM, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001, 61:7388.
280. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531.
281. Moseson DL, Sasaki GH, Kraybill WG, et al. The use of antiestrogens tamoxifen and nafoxidine in the treatment of human breast cancer in correlation with estrogen receptor values. A phase II study. Cancer 1978, 41:797.
282. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809.
283. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497.
284. Ueda K, Cornwell MM, Gottesman MM, et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986, 141:956.
285. Mauldin G, Matus R, Patnaik A, et al. Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats. J Vet Intern Med 1988, 2:60.
286. Herzog TJ, Krivak TC, Fader AN, et al. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol 2010, 203:68. e1.
287. Wakatsuki T, Irisawa A, Imamura H, et al. Complete response of anaplastic pancreatic carcinoma to paclitaxel treatment selected by chemosensitivity testing. Int J Clin Oncol 2010, 15:310.
288. Ugurel S, Schadendorf D, Pfohler C, et al. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res 2006, 12:5454.
289. Staib P, Staltmeier E, Neurohr K, et al. Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci. Br J Haematol 2005, 128:783.
290. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 2007, 104:13086.
291. Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 2001, 98:10787.
292. Potti A, Dressman HK, Bild A, et al. Retraction: Genomic signatures to guide the use of chemotherapeutics. Nat Med 2011, 17:135.
293. Bonnefoi H, Potti A, Delorenzi M, et al. Retraction-Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2011, 12:116.
294. Baggerly KA, Coombes KR Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology. Ann Appl Stat 2009, 3:1309.